Lisa Taliadoros

Partner-in-Charge Melbourne

Melbourne + 61.3.9101.6821 Perth + 61.2.8272.0529 Sydney + 61.2.8272.0500

Connect:

Share

Head of the Intellectual Property Practice in Australia, Lisa Taliadoros has more than 20 years of experience in IP disputes, including in relation to patents, trademarks, copyright, breach of confidence, and Australian Consumer Law (ACL) matters.

Lisa's practice includes acting in complex, multijurisdictional disputes in the Federal and High Court of Australia. This includes acting for clients in contentious patent matters across a range of industries, including pharmaceuticals, medical devices, life sciences, information systems, gaming, mining, and building & construction. Notably, Lisa has acted in the High Court of Australia in two landmark decisions concerning the scope of patent protection for Myriad's BRCA1 (breast cancer) patents and Sanofi's leflunomide patent for the treatment of skin disorders. In addition, Lisa has acted in numerous significant trademark disputes concerning consumer goods, credit payment and loyalty programs, and retail and B2B services.

Lisa is a member of the Intellectual Property Law Committee of the Law Council of Australia and convenor of the Patent Subcommittee.

Lisa's IP practice is recognized in numerous directories, including Chambers, The Legal 500, IP Stars, IAM Patent 1000, and Best Lawyers.

Prior to obtaining her law degree, Lisa was a scientist at two of Australia's preeminent research organizations, the CSIRO and the Centenary Institute of Cell Biology and Cancer Medicine. Her research projects involved the development of vaccines for avian infectious bronchitis virus and investigating the role of lymphotoxin alpha in the pathogenesis of autoimmune disorders.

Lisa is Partner-in-Charge of the Melbourne Office and serves as Jones Day's inclusion and advancement partner for Australia.

Experience

  • Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent OfficeJones Day is acting in an opposition proceeding for Sanofi and Regeneron in relation to their challenge to a portfolio of applications held by Amgen Inc. that claim anti-PCSK9 antibodies and their use in the treatment of hypercholesterolemia.
  • Myriad acts in High Court's first consideration of genetic material patentsJones Day acted for Myriad Genetics, Inc. in a landmark Australian case before the High Court of Australia.
  • ToolGen defends revolutionary CRISPR technology patentJones Day is acting for ToolGen, Inc. in relation to a challenge to its patent rights concerning CRISPR, a technology that has revolutionized the field of molecular biology including gene editing in the medical, biotechnology, and agricultural and farming industries.
  • Bradken successfully defends patent infringement case brought by CQMS concerning mining equipmentJones Day acted for Bradken Limited in its successful defense against claims made by CQMS Pty Ltd that Bradken infringed patents concerning ground engaging tools.
  • Idenix asserts patent infringement against Gilead in Australia related to Sovaldi® and Harvoni®Jones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in the Federal Court of Australia over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
    • View All

    July 2023 Commentary

    Amendments to Australia's Modern Slavery Act Anticipated Following Statutory Review

    July 2021 Newsletters

    Australian Court Holds That Use of a Corporate Logo for Purposes of Engaging in a Public Campaign Amounts to Mostly Fair Dealing

    July 2021 Newsletters

    The Climate Report | Third Quarter 2021

    April 2020 White Paper

    Quick Reference Guide: Compulsory Patent Licensing During COVID-19 Crisis

    September 2019 Alert

    Australia Repeals IP Exemptions From Antitrust Rules

    July 2018 Commentary

    Federal Court of Australia Grants First Interlocutory Injunction Against Biosimilar

    June 2018 Commentary

    High Court of Australia Settles Principles for Preliminary Discovery

    April 2018 Commentary

    IP Rights Reform Is Price to Pay for Revamped Trans-Pacific Partnership Agreement

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.